AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq ease from record highs as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
| AbbVie (NYSE: ABBV) | Delayed: 272.36 +5.67 (2.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $266.69 | 52 Week High | $68.12 | |||
| Open | $268.40 | 52 Week Low | $50.71 | |||
| Day High | $274.94 | P/E | 59.08 | |||
| Day Low | $266.89 | EPS | $4.61 | |||
| Volume | 2,821,148 | |||||
